ZAP Surgical Secures $36 Million in New Financing Led by Catalio Capital Management
ZAP Surgical Systems, Inc. announced on October 19, 2026, that it has secured $36 million in financing led by healthcare and artificial intelligence investment firm Catalio Capital Management, with continued backing from its Chinese strategic partner Baheal. The San Carlos-based medical technology company stated that the capital will support the global expansion of its non-invasive robotic brain surgery systems across leading academic medical centers, community hospitals, and physician-led practices.
The company recently shipped its 50th ZAP-X Gyroscopic Radiosurgery platform and is scaling production to meet rising global demand. According to company figures cited in the announcement, nearly 10,000 patients have been treated worldwide using the platform. Nicholas von Guionneau, M.D., Ph.D., of Catalio Capital Management joined ZAP’s board as an observer following the transaction.
Expanding Global Footprint and Commercial Milestones
The newly acquired funding aims to accelerate the deployment of the ZAP-X system, which is designed as a vault-free radiosurgery platform for treating brain tumors and other neurological conditions. ZAP Surgical Founder and CEO John R. Adler noted that scaling non-invasive, cost-effective therapy to tens of millions of patients globally requires strong partners. Baheal has driven the company’s presence in China, while Catalio’s strategic support will facilitate broader adoption throughout the U.S., the company reported.
ZAP Surgical Secures $36 Million Led by Catalio Capital Management to Scale Non-Invasive Brain Surgery – https://t.co/Iutaeq9b55
In addition to neuro-oncology applications, ZAP and its collaborators are exploring the use of low-dose ionizing radiation for psychiatric disorders—a process termed “radiomodulation.” Preliminary findings from a first-in-human pilot study evaluating patients with severe treatment-resistant depression were recently reported on MedRxiv. Based on those early outcomes, the company is planning broader multi-center clinical trials focusing on conditions including treatment-resistant depression and addiction.
Related reading